Only $35.99/year

PCL5W8 BBWs

Terms in this set (12)

Cardiovascular Events: Erythropoiesis-stimulating agents (ESAs) increase the risk of death, myocardial infarction (MI), stroke, venous thromboembolism, thrombosis of vascular access.

Chronic Kidney Disease: In controlled trials, patients experienced greater risks of death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of greater than 11 g/dL. No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks. Use the lowest epoetin alfa dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in some clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers. Because of these risks, health care providers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense epoetin alfa to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit http://www.esa-apprise.com or call 1-866-284-8089 for further assistance. To decrease these risks, as well as the risk of serious cardiovascular and thrombovascular events, use the lowest dose needed to avoid RBC transfusions. Use ESAs only for treatment of anemia from concomitant myelosuppressive chemotherapy. ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure. Discontinue following the completion of a chemotherapy course.

Perisurgery: Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended.
Cardiovascular Events: Erythropoiesis-stimulating agents (ESAs) increase the risk of death, myocardial infarction (MI), stroke, venous thromboembolism, thrombosis of vascular access.

Chronic Kidney Disease: In clinical trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of more than 11 g/dL.

No trial has identified a hemoglobin target level, darbepoetin alfa dose, or dosing strategy that does not increase these risks.

Use the lowest darbepoetin alfa dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Cancer: ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.

Because of these risks, health care providers and hospitals must enroll in and comply with the ESA APPRISE Oncology Program to prescribe and/or dispense darbepoetin alfa to patients with cancer. To enroll in the ESA APPRISE Oncology Program, visit http://www.esa-apprise.com or call 1-866-284-8089 for further assistance.

To decrease these risks, as well as the risk of serious cardiovascular and thrombovascular reactions, use the lowest dose needed to avoid RBC transfusion.

Use ESAs only for treatment of anemia from myelosuppressive chemotherapy.

ESAs are not indicated for patients receiving myelosuppressive therapy when the anticipated outcome is cure.

Discontinue following the completion of a chemotherapy course.